Acute Myeloid Leukemia Clinical Trial

A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)

Summary

The purpose of this study is to compare relapse-free survival between participants with FLT3/ITD AML in first morphologic complete remission (CR1) who undergo hematopoietic stem cell transplant (HCT) and are randomized to receive gilteritinib or placebo beginning after the time of engraftment for a two year period.

View Full Description

Full Description

Participants with FLT3/ITD AML in first morphologic complete remission (CR1) undergoing allogeneic hematopoietic stem cell transplant (HCT) will be randomized to receive gilteritinib or placebo 30 to 90 days after HCT for a two year period. Participants will be stratified according to: 1) conditioning regimen intensity (myeloablative vs. reduced intensity/non-myeloablative), 2) time from first day of hematopoietic cell infusion to randomization (30-60 days vs. 61-90 days) and 3) presence vs absence of or unknown minimal residual disease (MRD) from the most recent pre-registration bone marrow (BM) aspirate.

View Eligibility Criteria

Eligibility Criteria

Registration Inclusion Criteria

Participant is considered a suitable candidate for HCT and has an acceptable source of allogeneic donor stem cells, as defined per institutional practice (allogeneic HCT for any donor source [matched sibling, unrelated donor (URD), mismatched URD, related haploidentical, or umbilical cord blood] and any graft source [umbilical cord, BM, peripheral blood (PB)], and any conditioning [myeloablative conditioning (MAC), reduced intensity conditioning (RIC), or non-myeloablative conditioning (NMA)] will be permitted).
Participant is considered a legal adult by local regulation at the time of signing informed consent form (ICF).
Participant consents to allow access to diagnostic BM aspirate or PB sample and/or the DNA derived from that sample, if available, that may be used to validate a companion diagnostic that is being developed in parallel with gilteritinib.

Participant has confirmed, morphologically documented AML in CR1. For the purposes of registration, CR1 will be defined as < 5% blasts in the BM with no morphologic characteristics of acute leukemia (e.g., Auer Rods) in the BM with no evidence of extramedullary disease such as central nervous system involvement or granulocytic sarcoma.

Participant has not received more than 2 cycles of induction chemotherapy to achieve CR1. The induction cycles can be the same regimen or different regimens. The regimen(s) may contain conventional agents, investigational agents, or a combination of both.
Participants with CR with incomplete count recovery (CRp or CRi) are allowed. Incomplete platelet recovery (CRp) is defined as CR with platelet count < 100 x 109/L. Incomplete blood count recovery (CRi) is defined as CR with residual neutropenia < 1 x 109/L with or without complete platelet recovery. Red blood cell count (RBC) and platelet transfusion independence is not required.
The maximum time allowed from establishment of CR1 to registration is 12 months.
Participant has presence of the FLT3/ITD activating mutation in the BM or PB as determined by the local institution at diagnosis.

Participant must meet the following criteria as indicated on the clinical laboratory tests:

Serum creatinine within normal range, or if serum creatinine outside normal range, then glomerular filtration rate (GFR) > 40 mL/min/1.73m2 as calculated with the Cockcroft-Gault equation with adjustment if total body weight is ≥ 125% of ideal body weight.
Total bilirubin (TBL) ≤ 2.5 mg/dL, except for participants with Gilbert's syndrome.
Serum AST and/or alanine aminotransferase (ALT) < 3 x institutional upper limit of normal (ULN).
Participant has left ventricular ejection fraction at rest ≥ 40%.
Participant has diffusing capacity of the lung for carbon monoxide (DLCO) (corrected for hemoglobin) ≥ 50% predicted and/or forced expiratory volume in 1 second (FEV1) ≥ 50% predicted.

Female participants must either:

Be of non-childbearing potential:
postmenopausal (defined as at least 1 year without menses) prior to screening or
documented as surgically sterilized (at least 1 month prior to the screening visit)

Or, if of childbearing potential,

Agree not to try to become pregnant during the study for 6 months after the final study drug administration
And have a negative serum pregnancy test at screening
And, if heterosexually active, agree to consistently use highly effective contraception per locally accepted standards in addition to a barrier method starting at screening and throughout the study period and for 6 months after the final study drug administration.
For United Kingdom sites:
Highly effective forms of birth control include:
Consistent and correct usage of established hormonal contraceptives that inhibit ovulation
Established intrauterine device (IUD) or intrauterine system (IUS)
Female participants must agree not to breastfeed or donate ova throughout the study drug treatment period and for 6 months after the final study drug administration.

Male participants (even if surgically sterilized), and partners who are women of childbearing potential must be using highly effective contraception in addition to a barrier method throughout the study drug treatment period and for 127 days after the final study drug administration.

For United Kingdom sites:
Highly effective forms of birth control include:
Consistent and correct usage of established hormonal contraceptives that inhibit ovulation
Established IUD or IUS
Vasectomy (A vasectomy is a highly effective contraception method provided the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used.)
Male is sterile due to a bilateral orchiectomy
Male participants must not donate sperm throughout the study drug treatment period and for 127 days after the final study drug administration.
Participant is able to take an oral medication.
Participant agrees not to participate in another interventional study while on treatment.

Randomization Inclusion Criteria

Participant is ≥ 30 days and ≤ 90 days from hematopoietic cell infusion.
Participant has achieved engraftment. Engraftment is defined as ANC ≥ 500 cells/μL and platelets ≥ 20000/μL on 3 consecutive measurements (each occurring at least 1 day apart). The participant must not have had a platelet transfusion within 7 days prior to the first measurement.
Participant has confirmed ongoing morphologically documented AML in CR1. For the purposes of randomization, CR1 will be defined as < 5% blasts with no morphologic characteristics of acute leukemia (e.g., Auer Rods) in the BM with no evidence of extramedullary disease such as central nervous system involvement or granulocytic sarcoma.

Participant meets the following criteria as indicated on the clinical laboratory tests:

Serum creatinine within normal range, or if serum creatinine outside normal range, then GFR > 40 mL/min/1.73m2 as calculated with the Cockcroft-Gault equation with adjustment if total body weight is ≥ 125% of ideal body weight.
TBL < 2.5 mg/dL, except for participants with Gilbert's syndrome.
Serum AST and/or ALT < 3 x institutional ULN.
Serum potassium and magnesium ≥ the institutional lower limit of normal (LLN).

If the participant has developed overall grades II-IV acute GVHD, the following criteria must be met to be randomized:

No requirement of > 0.5 mg/kg of prednisone (or equivalent) daily dose within 1 week of randomization
No escalation of systemic immunosuppression in terms of increase of corticosteroids or addition of new agent / modality within 2 weeks of randomization. (Note that increasing calcineurin inhibitors or sirolimus to achieve therapeutic trough levels is allowed.) Topical skin and topical gastrointestinal steroids are allowed.
Participant is able to take oral medication.

Registration Exclusion Criteria

Participant has had a prior allogeneic transplant.
Participant has Karnofsky performance status score < 70% .
Participant requires treatment with concomitant drugs that are strong inducers of CYP3A within 14 days of start of study drug.
Participant requires treatment with concomitant drugs that target serotonin 5-hydroxytryptamine receptor 1 (5HT1R) or 5-hydroxytryptamine receptor 2B (5HT2BR) or sigma nonspecific receptor with the exception of drugs that are considered absolutely essential for the care of the participant.
Participant has a Fridericia-corrected QT interval (QTcF) > 450 msec (average of triplicate determinations) per central read.
Participant has long QT Syndrome at screening.
Participant has a known infection with human immunodeficiency virus (HIV).
Participant has active hepatitis B infection as determined by NAAT or surface antigen assay. Participants who have acquired immunity from past exposure (HBcAb positive / HBsAb positive / HBsAg negative) are eligible.
Participant has active hepatitis C infection as determined by NAAT. NAAT must be performed if the participant has positive serology for hepatitis C. Participants who have had past exposure and have no detectable virus either through spontaneous clearance or treatment are eligible.

Participant has an uncontrolled infection. If a bacterial or viral infection is present, the participant must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to registration. If a fungal infection is present, the participant must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to registration.

Progressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection.
Persisting fever without other signs or symptoms will not be interpreted as progressing infection.
Participant has had a myocardial infarction within 6 months prior to registration or New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia.
Participant has a serious medical or psychiatric illness likely to interfere with participation in this clinical study.
Participant is breast feeding or pregnant.
Participant has prior malignancies, except lobular breast carcinoma in situ, fully resected basal cell or squamous cell carcinoma of skin or treated cervical carcinoma in situ.

Cancer treated with curative intent ≥ 5 years previously will be allowed. Cancer treated with curative intent < 5 years previously will not be allowed.

Randomization Exclusion Criteria

Participant requires treatment with concomitant drugs that are strong inducers of CYP3A within 14 days of starting study drug.
Participant requires treatment with concomitant drugs that target serotonin 5HT1R or 5HT2BR or sigma nonspecific receptor with the exception of drugs that are considered by the investigator to be absolutely essential for the care of the participant and for which no acceptable alternative exists.
Participant has a QTcF interval > 450 msec (average of triplicate determinations) by central read.
Participant has a need for supplemental oxygen with the exception of using previously existing non-invasive continuous positive airway pressure (CPAP) at night.
Participant has used investigational agents within 4 weeks of randomization.
Participant has used experimental therapy for acute GVHD within 4 weeks of randomization. If unsure of the definition of "experimental", discussion with one of the protocol chairs is recommended.

Participant has an uncontrolled infection. If a bacterial or viral infection is present, the participant must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to randomization. If a fungal infection is present, the participant must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to randomization.

Progressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection.
Persisting fever without other signs or symptoms will not be interpreted as progressing infection.

Study is for people with:

Acute Myeloid Leukemia

Phase:

Phase 3

Estimated Enrollment:

356

Study ID:

NCT02997202

Recruitment Status:

Completed

Sponsor:

Astellas Pharma Global Development, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 47 Locations for this study

See Locations Near You

University of Alabama at Birmingham
Birmingham Alabama, 35294, United States
Mayo Clinic
Phoenix Arizona, 85054, United States
Virginia G Piper Cancer Center
Scottsdale Arizona, 85258, United States
University of California San Francisco
San Francisco California, 94143, United States
Stanford University
Stanford California, 94305, United States
Yale University School of Medicine
New Haven Connecticut, 06511, United States
University of Florida
Gainesville Florida, 32610, United States
University of Miami
Miami Florida, 33136, United States
H. Lee Moffitt Cancer Center
Tampa Florida, 33612, United States
Emory University
Atlanta Georgia, 30322, United States
Northside
Atlanta Georgia, 30342, United States
Augusta University
Augusta Georgia, 30912, United States
Northwestern Memorial Hospital
Chicago Illinois, 60611, United States
Rush University Medical Center
Chicago Illinois, 60612, United States
Loyola University Medical Center
Maywood Illinois, 60153, United States
Indiana Blood and Marrow Transplant
Indianapolis Indiana, 46237, United States
University of Kansas Medical Center
Kansas City Kansas, 66160, United States
University of Maryland Medical Systems
Baltimore Maryland, 21201, United States
Johns Hopkins Hospital
Baltimore Maryland, 21231, United States
Massachusetts General Hospital
Boston Massachusetts, 02114, United States
Beth Israel Deaconess Medical Center
Boston Massachusetts, 02215, United States
Dana Farber Cancer Institute
Boston Massachusetts, 02215, United States
University of Massachusetts
Worcester Massachusetts, 01655, United States
Karmanos Cancer Center
Detroit Michigan, 48201, United States
University of Minnesota School of Medicine
Minneapolis Minnesota, 55455, United States
Mayo Clinic
Rochester Minnesota, 55905, United States
Washington University in St. Louis
Saint Louis Missouri, 63110, United States
University of Nebraska Medical Center
Omaha Nebraska, 68198, United States
Memorial Sloan Kettering
New York New York, 10065, United States
Weill Cornell Medical Center
New York New York, 10065, United States
University of North Carolina
Chapel Hill North Carolina, 27599, United States
Duke University Medical Center
Durham North Carolina, 27710, United States
Wake Forest Baptist Health
Winston-Salem North Carolina, 27157, United States
University Hospitals of Cleveland Medical Center
Cleveland Ohio, 44106, United States
Cleveland Clinic
Cleveland Ohio, 44195, United States
Ohio State University, The
Columbus Ohio, 43210, United States
Oregon Health and Science University
Portland Oregon, 97239, United States
University of Pennsylvania
Philadelphia Pennsylvania, 19104, United States
Vanderbilt University Medical Center
Nashville Tennessee, 37232, United States
Baylor College of Medicine
Houston Texas, 77030, United States
Huntsman Cancer Institute
Salt Lake City Utah, 84143, United States
Intermountain BMT
Salt Lake City Utah, 84143, United States
Fred Hutchinson Cancer Research Center
Seattle Washington, 98109, United States
West Virginia University Hospital
Morgantown West Virginia, 26506, United States
University of Wisconsin Hospital and Clinics
Madison Wisconsin, 53792, United States
Medical College of Wisconsin
Milwaukee Wisconsin, 53226, United States
Site AU61001
Liverpool , , Australia
Site AU61002
Melbourne , , Australia
Site AU61004
Westmead , , Australia
Site BE32003
Bruxelles , , Belgium
Site BE32004
Gent , , Belgium
Site CA15004
Hamilton , , Canada
Site CA15003
Montreal , , Canada
Site DK45002
Arhus , , Denmark
Site DK45001
Copenhagen , , Denmark
Site FR33007
Lille , , France
Site FR33004
Lyon , , France
Site FR33005
Paris , , France
Site FR33008
Pessac , , France
Site FR33010
Vandoeuvre-Les-Nancy , , France
Site DE49002
Düsseldorf , , Germany
Site DE49003
Halle (Saale) , , Germany
Site DE49005
Hamburg , , Germany
Site DE49006
Köln , , Germany
Site DE49007
Mainz , , Germany
Site DE49004
Münster , , Germany
Site GR30004
Athens , , Greece
Site GR30003
Rio , , Greece
Site GR30001
Thessaloniki , , Greece
Site IT39005
Bergamo , , Italy
Site IT39006
Bologna , , Italy
Site IT39009
Genova , 16132, Italy
Site IT39002
Milano , , Italy
Site IT39007
Milano , , Italy
Site IT39011
Pescara , , Italy
Site IT39003
Roma , , Italy
Site IT39004
Udine , , Italy
Site JP81014
Anjo Aichi, , Japan
Site JP81011
Nagoya Aichi, , Japan
Site JP81018
Sapporo Hokkaido, , Japan
Site JP81021
Kobe Hyogo, , Japan
Site JP81012
Nishinomiya Hyogo, , Japan
Site JP81002
Isehara Kanagawa, , Japan
Site JP81007
Yokohama Kanagawa, , Japan
Site JP81010
Sendai Miyagi, , Japan
Site JP81006
Suita Osaka, , Japan
Site JP81008
Shimotsuke Tochigi, , Japan
Site JP81013
Bunkyo-ku Tokyo, , Japan
Site JP81004
Chuo-ku Tokyo, , Japan
Site JP81016
Minato-ku Tokyo, , Japan
Site JP81020
Shinjuku-ku Tokyo, , Japan
Site JP81001
Fukuoka , , Japan
Site JP81003
Fukuoka , , Japan
Site JP81015
Kyoto , , Japan
Site JP81017
Okayama , , Japan
Site JP81005
Osaka , , Japan
Site KR82001
Seoul , , Korea, Republic of
Site KR82002
Seoul , , Korea, Republic of
Site KR82003
Seoul , , Korea, Republic of
Site KR82004
Seoul , , Korea, Republic of
Site KR82005
Seoul , , Korea, Republic of
Site NZ64002
Christchurch , , New Zealand
Site NZ64001
Grafton , 1010, New Zealand
Site PL48004
Warszawa , , Poland
Site ES34004
Barcelona , 08036, Spain
Site ES34005
Barcelona , , Spain
Site ES34006
Salamanca , , Spain
Site ES34007
Santander , , Spain
Site ES34002
Valencia , , Spain
Site TW88603
Taichung , , Taiwan
Site TW88602
Taipei , , Taiwan
Site TW88605
Taoyuan , , Taiwan
Site GB44010
Birmingham , , United Kingdom
Site GB44003
Bristol , , United Kingdom
Site GB44009
Glasgow , G12 0, United Kingdom
Site GB44004
London , , United Kingdom
Site GB44002
Manchester , , United Kingdom
Site GB44001
Sutton , , United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Acute Myeloid Leukemia

Phase:

Phase 3

Estimated Enrollment:

356

Study ID:

NCT02997202

Recruitment Status:

Completed

Sponsor:


Astellas Pharma Global Development, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.